Gauthier_2025_Handb.Clin.Neurol_211_155

This chapter describes how the clinical efficacy of orally administered cholinesterase inhibitors has been demonstrated through placebo-controlled randomized clinical trials leading to regulatory approval worldwide for the symptomatic treatment of Alzheimer disease. Over time, other clinical indications have been found, such as Dementia with Lewy Bodies and Parkinson disease Dementia. The route of administration includes transdermal patches. Side effects predominantly arise from peripheral parasympathetic stimulation. There is hope that drugs acting on acetylcholine release or on muscarinic receptors can exert additional symptomatic benefits.